CareDx, Inc. (NASDAQ:CDNA) Receives $26.67 Consensus PT from Analysts

Shares of CareDx, Inc. (NASDAQ:CDNA) have received a consensus rating of “Hold” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $26.6667.

CDNA has been the subject of several recent research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of CareDx in a research note on Monday. BTIG Research increased their target price on shares of CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Zacks Research upgraded shares of CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Wells Fargo & Company increased their price objective on CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Finally, Wall Street Zen upgraded CareDx from a “hold” rating to a “buy” rating in a report on Sunday.

CareDx Stock Down 1.4%

NASDAQ:CDNA opened at $19.73 on Monday. CareDx has a 52 week low of $10.96 and a 52 week high of $25.95. The stock’s fifty day moving average is $17.02 and its two-hundred day moving average is $15.85. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 16.58 and a beta of 2.54.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.15. CareDx had a return on equity of 20.15% and a net margin of 19.65%.The business had revenue of $100.06 million during the quarter, compared to analysts’ expectations of $95.25 million. During the same period in the previous year, the firm posted ($0.14) earnings per share. The company’s revenue was up 20.7% on a year-over-year basis. On average, sell-side analysts expect that CareDx will post -0.9 EPS for the current fiscal year.

Institutional Trading of CareDx

Several hedge funds have recently added to or reduced their stakes in the company. MCF Advisors LLC lifted its stake in CareDx by 292.9% in the second quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock worth $26,000 after acquiring an additional 996 shares during the last quarter. Cetera Trust Company N.A lifted its position in shares of CareDx by 11.2% during the 2nd quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock worth $238,000 after purchasing an additional 1,225 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of CareDx by 5.9% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 22,509 shares of the company’s stock worth $440,000 after purchasing an additional 1,264 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in CareDx by 4.8% in the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after buying an additional 1,280 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in CareDx by 12.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 11,885 shares of the company’s stock valued at $232,000 after buying an additional 1,293 shares in the last quarter.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.